Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
eNq1mFFv2jAQx9/5FFHeSaDAoFOg2ljZkFqN0aJNe0EmOYpZsNOzDXSffg6hGp0cdXXwAw/Yzv8uvr9/PiW62m9SbwsoKGd9vxk0fA9YzBPKHvr+7H5U7/lXg1q0JltysqwbNILmhe/FKRGi7+ezwQIIE8GP25tPoJ8H9Ac1L+KLNcTyxTolaRp8IWJ1S7J8jRdtOU28DcgVT/p+puRh1IuERJ3FYMfxl8hIDFF4HDmdXc/bp+NRmIv9h6oSgDeEPRhFgVlpxgoRmBwSCQ8cn0rybVlpUzEFwRXGMCFyNUG+pQkkxhBLkgqwCrLcJXeA2xRkHsQoHq7jjbASJ2uyn8Lj2Jz0Bz07lHtZb9Sb3V6zq3+XvXetjlUoPNkqcxX0S4TZvNW+bLQ6bcuCTDhKkjoqBRXDl25yFAfh8dWSJ1RkKXkK1iKz3SqCRE8D6jPv7kXyN7hHTaFU79k/+kylafjGrGdHRjjKOEfQkCsmS1AxmtpuxJAzCfvyitrRTe6PXqQgzif7mzMz2SdqkdLYlmOaNAqEnE3H5RirTICPRMAM3SHgO2UJ34nzo+W0lI6yzw50NIpmmDTnFxrvzU7H+uT81L4puUuuFfIMQg0dKqqwZMyWvCpFtBXNUs9GrObBQxvDY5JCSSNTt6SINt9z3+XM3u6OTjFhFP18fW/riW8K8Onu8NcoTZN+tWrGLritHVia+Nv9XBxrJy2uQjMuVlJm4n0Y7na7YEVEXRC9S8ESz8Pwk7vSXVft5EIuGpSCg45SXxQX3NvKYnu8Xruyq7ahx+eP7a4xhkQFFWpRkNgZL8fX50fw3x7UWdqTF8hwF+bQLxJJOXPV0qiFuZ+piKAxG6EGxNflkpZ85Sj1ZRQWX1gGtSjMv64Man8Arf7Ujw==
VjvB9Se9GeA6cH5T